EP Patent

EP1555022A1 — Sustained release compound of acetamidophenol and tramadol

Assigned to WANG, JIN · Expires 2005-07-20 · 21y expired

What this patent protects

A sustained release formulation as a unit dose contains 100 mg - 1000 mg of Acetaminophen and 15 mg - 150 mg of tramadol hydrochloride, which comprises of 1) an immediate release portion comprising of 25% - 75% of the total effective amount of drug in the dosage form and 2) a sus…

USPTO Abstract

A sustained release formulation as a unit dose contains 100 mg - 1000 mg of Acetaminophen and 15 mg - 150 mg of tramadol hydrochloride, which comprises of 1) an immediate release portion comprising of 25% - 75% of the total effective amount of drug in the dosage form and 2) a sustained release portion comprising of a) 25% - 75% of the total effective amount of drugs in the dosage form; b) 6% - 50% of gelling polymers of the total formulation, and c) optionally an enteric coating at a level of 5% - 40% of the total formulation. The set forth formulation dissolves 25% - 60% of the total drug in the first hour, 50% - 90% of the total drug in the first four hours and not less than 80% of the total drug in the first 12 hours using USP dissolution method II at 50 rpm.

Drugs covered by this patent

Patent Metadata

Patent number
EP1555022A1
Jurisdiction
EP
Classification
Expires
2005-07-20
Drug substance claim
No
Drug product claim
No
Assignee
WANG, JIN
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.